findmyKOL

Erin Amerson, MD

Basic profile

San Francisco General Hospital

ORCIDNPI
RegionSan Francisco, CA · WestSpecialtyDermatologyFocusDermatology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Erin Amerson is a Dermatology physician affiliated with San Francisco General Hospital. OpenAlex indexes 80 publications with 1,540 citations (h-index 17).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
80publications

Distinct works indexed by OpenAlex, matched via ORCID.

1,540citations

Total citations across indexed works.

17h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1701 Divisadero St
3rd Floor
San Francisco, CA 941153011

Telephone

415-353-7800

Registry record last updated 29 Feb 2012.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Dermatology

    27.3%
    Corticosteroid11.6%
    Triamcinolone Acetonide85%Fluocinolone Acetonide15%
    Part D<11 patients
    Interleukin-4 Receptor alpha Antagonist11.1%
    Dupixent Syringe67%Dupixent Pen33%
    Part D<11 patients

    + 4 more classes in this area

  • Cancer & immunology

    20.9%
    Folate Analog Metabolic Inhibitor4.4%
    Methotrexate100%
    Part D13 patients
    TNF inhibitor4.4%
    Humira Pen57%Humira(Cf) Pen43%
    Part D<11 patients

    + 7 more classes in this area

  • Anti-infectives

    20.3%
    Azole Antifungal13%
    Ketoconazole100%
    Part D90 patients
    Lincosamide Antibacterial2.5%
    Clindamycin Phosphate56%Clindamycin Hcl44%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”